CAMK2G is identified as a novel therapeutic target for myelofibrosis

Although JAK1/2 inhibition is effective in alleviating symptoms of myelofibrosis (MF), it does not result in the eradication of MF clones, which can lead to inhibitor-resistant clones emerging during the treatment. Here, we established induced pluripotent stem cells (iPSCs) derived from MF patient s...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyauchi, Masashi, Sasaki, Ken, Kagoya, Yuki, Taoka, Kazuki, Masamoto, Yosuke, Yamazaki, Sho, Arai, Shunya, Mizuno, Hideaki, Kurokawa, Mineo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905705/
https://www.ncbi.nlm.nih.gov/pubmed/34521112
http://dx.doi.org/10.1182/bloodadvances.2020003303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905705/
https://www.ncbi.nlm.nih.gov/pubmed/34521112
http://dx.doi.org/10.1182/bloodadvances.2020003303

Ejemplares similares